The COVID-19 crisis left organizations in a tough spot. How boards reacted in the face of this pressure may leave them liable, according to recent situations with similar outbreaks and illnesses.
In the U.S., where health insurance through an employer is the primary way to receive care, many patients may abstain from going to the doctor due to costs. This has the potential to further the spread of the virus and has put insurers in the spotlight.
Chipotle Mexican Grill informed shareholders that it would reduce the size of the board by three directors when it announced its founder was stepping away from the company. In what situations does a reduced board make sense? It depends on the complexity of the business — but oftentimes, slimmer works better.
The cost of epidemics is expected to rise by $23.5 trillion over the next 30 years, as the rates of the such illnesses increase. The coronavirus has shown that such an epidemic halts business and can impact all parts of the company, from the supply chain to how employees work.
JPMorgan Chase & Co. announced that Chairman and CEO Jamie Dimon had to undergo emergency heart surgery. An emergency medical situation – or worse – impacting the person in the CEO role can forever damage a company, a scare that no board wants to deal with. But they can prepare, just in case.
For many years, director compensation was overshadowed by executive pay. But due to recent litigation, more shareholders and oversight organizations keep a close eye on the decisions made by your compensation committee. Without a clear pay growth strategy, then the company risks financial and public backlash.
The New York Times has reported that executives at Walgreens Boots Alliance asked consultants to remove findings from an internal report that included complaints from its employees. For a better way of making sure information isn’t hidden from the board, look towards this technology darling.
The number of companies using artifiicial intelligence within at least one department of their organization grew by nearly 25% last year. If your firm is just getting started on testing AI, here are three key considerations.
The healthcare industry has been a fountain of dealmaking lately. Companies wanting to make acquisitions or sell businesses this year should learn from the experts.
Investors are asking more about a company’s workforce, and companies may be forced to tell them. Last fall, the U.S. Securities and Exchange Commission proposed several changes to disclosure requirements for public companies, among them a provision to enhance disclosure about “human capital.” The rule has not been finalized.